Encouraging Phase II data doubled Capricor Therapeutics’ (Nasdaq: CAPR) share price on Monday, amid modest volumes of trade in New York.
An interim analysis of results six months into the HOPE-2 trial showed statistically-significant outcomes for lead Duchenne muscular dystrophy (DMD) candidate CAP-1002, across several clinical measures.
Capricor is working on first-in-class therapies using allogeneic cardiosphere-derived cells, or CDCs, which are thought to have therapeutic potential in modulating the immune system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze